The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Oral cyclophosphamide (Cyc) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A retrospective cohort from a tertiary public cancer center in Brazil.
 
Yumi Ricucci Shinkado
No Relationships to Disclose
 
Diana Del Cisne Pineda Labanda
No Relationships to Disclose
 
Gabriel Berlingieri Polho
No Relationships to Disclose
 
Gustavo Alves Contado
No Relationships to Disclose
 
Nathália de Souza Del Rey Crusoé
No Relationships to Disclose
 
Vivian Horita
No Relationships to Disclose
 
João Carlos Resende Martins
No Relationships to Disclose
 
Guilherme Fialho de Freitas
No Relationships to Disclose
 
David Queiroz Borges Muniz
Consulting or Advisory Role - Janssen Oncology
Speakers' Bureau - Bayer; BMS Brazil; Ferring; Janssen
Research Funding - Pfizer (Inst)
 
Jose Mauricio Mota
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Ipsen; Janssen; Merck; Pfizer; Zodiac Pharma
Consulting or Advisory Role - Astellas Pharma; Janssen Oncology
Speakers' Bureau - Amgen; Astellas Pharma; AstraZeneca; Bayer; Ipsen; Janssen Oncology; Merck; Pfizer; Zodiac Pharma
Expert Testimony - Astellas Pharma; Bayer
Travel, Accommodations, Expenses - Janssen Oncology; Zodiac Pharma